Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the...
Neurocrine Biosciences Neurocrine Biosciences Inc Drug Administration Prnewswire Neurocrine Biosciences Inc Met Primary Endpoint Demonstrating Statistically Significant Decrease
Source: prnewswire.com